the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
PHASE2WithdrawnINTERVENTIONAL
0
Timeline
Start Date
April 30, 2020
Primary Completion Date
December 31, 2020
Study Completion Date
March 31, 2021
Conditions
HIV-1 Infection
Interventions
BIOLOGICAL
UB-421
Monoclonal antibody by IV infusion plus standard ART